Celltrion Considers US Manufacturing In Response To Trump Tariffs

Measures Also Include Securing US Inventory And Focus On Drug Substance Imports

Celltrion may consider establishing or acquiring US manufacturing facilities as well as securing more US inventory and shifting its focus onto drug substance rather than drug product imports, the Korean biosimilars giant has suggested, as it sought to assuage investor concerns over pharmaceutical tariffs announced by US president Donald Trump.

Celltrion has plans to deal with any US tariffs (Shutterstock)

Establishing a US production base, focusing on drug substance imports over drug product imports, and building up US inventory are all ways in which Celltrion could mitigate US pharmaceutical tariffs announced by US president Donald Trump, the Korean biosimilars specialist has indicated in response to investor concerns.

Acknowledging that “in a recent speech shortly after his inauguration, US President Donald Trump briefly mentioned that, along with semiconductors and steel, foreign-produced pharmaceuticals would also be subject to tariffs,” Celltrion said that “some of our shareholders have expressed concerns regarding this statement.”

In response, the firm set out a series of short-term, medium-term and longer-term measures that it could take to minimize the impact of any tariffs – although at the same time, Celltrion pointed out that “to date, president Trump has not presented specific policy proposals regarding drug tariffs, and the actual implementation is still uncertain, requiring further review and policy observation.”

Moreover, the firm observed, tariffs on pharmaceuticals “could lead to rising drug prices in the US, imposing significant burdens on consumers and the healthcare system. Therefore, it is unclear whether president Trump will actually enforce such measures. Notably, during his first term, president Trump consistently pushed for lower drug prices, and this tariff policy would directly contradict his previous stance on drug pricing.”

Nevertheless, Celltrion said it had “closely analyzed various scenarios regarding the possibility of tariffs and have already in place a system capable of responding immediately, regardless of how the policy is implemented.”

Inventory, Import Mix, And Local Manufacturing

In the short-term, Celltrion said that it currently had sufficient inventory of its products in the US to meet demand “until at least the third quarter of 2025, without the need for additional imports.” And for products that are expected to be depleted sooner, “we have the capability to produce finished pharmaceuticals from active pharmaceutical ingredients already imported to the US.”

However, in the company said that “if tariffs are sustained in the long term, we plan to focus on exporting drug substances, which are subject to lower tariffs, rather than finished drug products that face higher tariffs, and adjust our strategy to produce finished drug products at local manufacturing sites.” In connection with this, Celltrion said it was “already exploring cooperation with local companies that have sufficient manufacturing capacity to produce our products.”

Finally, in the long-term, the company said that it was evaluating potentially acquiring or establishing local US manufacturing facilities that would be capable of producing both finished drug products and drug substances. “This would help us create a stable supply chain that is less affected by political and social changes in the US, while also expanding our market share in the US,” the firm suggested.

Meanwhile, Celltrion also pointed to the likely wider impact of any such moves by the new US president. “If the Trump administration imposes tariffs,” the company suggested, “it is likely to increase the prices of consumer goods and raw materials in the US, leading to inflation.” And “if inflation worsens, there is a higher possibility that the US Federal Reserve will continue its tight monetary policy, which could result in sustained high exchange rates.”

“A high exchange rate environment can be beneficial for global export companies like us,” Celltrion underlined, “enhancing our competitiveness in the US market and improving profitability.”

“In conclusion,” Celltrion said, “we will continue to monitor the Trump administration’s tariff policy direction and are fully prepared to respond immediately if the policy is enacted. Moreover, in light of the changes in the global economic environment, we will leverage exchange rate fluctuations to maintain a stable profit structure and actively pursue long-term growth strategies. Additionally, we will strive to minimize supply and sales risks and maximize shareholder value through sustainable growth.”

More from Strategy

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence

 
• By 

With sales remaining sluggish, on the back of fewer launches, Glenmark’s management nevertheless struck an upbeat tone when discussing the firm’s prospects in the US moving into the company’s 2026 financial year.

More Stelara Rivals Hit US, With Discounts Already Reaching 85%

 
• By 

As more Stelara biosimilars pile into the US market – including launches from Alvotech/Teva, Samsung Bioepis/Sandoz and Biocon – the latest data suggests that price competition for ustekinumab rivals could be fierce, with Teva and Sandoz both confirming to Generics Bulletin details of significant discounts to the brand.

With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus

 
• By 

Reformulation specialist Lipella has an eye on numerous milestones for its proposed oral rinse liposomal formulation of tacrolimus, including the submission of a Phase IIb clinical trial investigational new drug application.

Alvotech Eyeing US Aflibercept Biosimilar Approval This Year With FDA Acceptance

 
• By 

Alvotech has followed its European filing for a biosimilar to Regeneron’s Eylea (aflibercept) 2mg with acceptance for review from the US Food and Drug Administration for its AVT06 candidate.

More from Policy & Regulation

Aurobindo: US Tariffs ‘Not A Challenge’ For Now, Scouting For Biosimilars Tie-Ups

 
• By 

A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26.

Feedback Sought To Shape Highly Awaited EU Law On Cutting Dependency On Asian Imports

 

Momentum is building around the European Commission’s race to propose a Critical Medicines Act, which aims to tackle drug shortages and create a better framework for establishing manufacturing facilities of essential medicines in the EU.

AAM Stares Into The Biosimilar Void

 
• By 

Discussing a new report highlighting the lack of US biosimilar competition on the cards for the majority of biologics losing exclusivity in the next ten years, the AAM’s Access! 2025 conference heard that the “sobering” findings should act as a “wake-up call for stakeholders.”